Genital Diseases, Female  >>  nintedanib  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
nintedanib / Generic mfg.
NCT00710762 / 2005-002427-14: A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer

Completed
2
89
Europe
BIBF1120, Placebo
Boehringer Ingelheim
Ovarian Neoplasms
09/08
03/14
NCT01225887: Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Completed
2
37
US
Nintedanib, BIBF 1120, BIBF-1120, Intedanib, Multitargeted Tyrosine Kinase Inhibitor BIBF 1120, tyrosine kinase inhibitor BIBF 1120, Vargatef
Gynecologic Oncology Group, National Cancer Institute (NCI)
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Transitional Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm, Recurrent Uterine Corpus Carcinoma
01/16
01/16
NCT01669798: BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

Completed
2
32
US
BIBF 1120, Vargatef™, Nintedanib
AA Secord, Boehringer Ingelheim
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
09/17
02/18

Download Options